Forbes Ranks BioReliance #1 in Earnings Per Share Growth on Annual List of 200 Entrepreneurial Growth Companies

Forbes Ranks BioReliance #1 in Earnings Per Share Growth on Annual List of 200
Entrepreneurial Growth Companies 


ROCKVILLE, Md., Oct. 27  /PRNewswire-FirstCall/ -- BioReliance Corporation 
announced today that it has been named to Forbes magazine's annual list of "Hot
Shots: 200 Up and Coming Companies" for 2003.  BioReliance was ranked "Number 1"
in Earnings per Share Growth over the past five years and number 139 overall
among this select group of smaller public companies.

In developing its annual ranking, Forbes collaborated with William O'Neil &
Company in the compilation of the list of 200, which consists of fast growing,
profitable public companies with revenues between $5 million and $600 million. 
For the final ranking, equal weight was given to growth in sales, earnings and
return on equity for the past five years and the latest 12 months.  Appearing
for the first time on the annual listing, BioReliance was ranked number 139
overall and "Number 1" in earnings per share growth among the 200 companies
comprising the list.

Capers McDonald, President and Chief Executive Officer of BioReliance, said, "We
are honored in this recognition by Forbes.  We believe that it reflects, in
part, the high level of dedication by everyone at BioReliance to the
productivity and growth of our company. This result, accomplished over the past
five years, is driven by our ongoing efforts in quality, science and service. 
We are committed to providing our customers with the very highest levels of
support, wherever we do business, and to increasing shareholder value in that
process."

About BioReliance

BioReliance Corporation is a leading, global contract service organization
providing integrated testing, development and manufacturing services for
biologics and other biomedical products to biotechnology and pharmaceutical
companies worldwide. The Company believes it is the largest provider of
outsourcing services focused on the expanding biologics sector of the
pharmaceutical industry.

This press release contains forward-looking statements that describe certain
BioReliance communications. As and when made, management believes that these
forward-looking statements are reasonable.  BioReliance undertakes no obligation
to revise or publicly release the results of any revision to these
forward-looking statements.  Therefore, readers are cautioned not to place undue
reliance on these forward-looking statements since new risk factors emerge from
time to time, and it is not possible for management to predict all such risk
factors, nor can it assess the impact of all such risk factors on BioReliance's
business or the extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any forward-looking
statements. 

DATASOURCE: BioReliance Corporation



CONTACT:  John L. Coker, Sr. Vice President, Finance and Administration

and Chief Financial Officer of BioReliance Corporation, [phone]; or

General Info, Marilynn Meek, [phone], or Analysts, Julie Tu,

[phone], both of FRB Weber Shandwick

Copyright